Crossmark

Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy

Crossref DOI link: https://doi.org/10.1186/s12916-022-02614-8

Published Online: 2022-10-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cheng, Yibin

Wang, Caixia

Wang, Huihui

Zhang, Zhiwei

Yang, Xiaopeng

Dong, Yanming

Ma, Lixin

Luo, Jingwen https://orcid.org/0000-0003-0675-6338
License Information

Text and Data Mining valid from 2022-10-28

Version of Record valid from 2022-10-28
More Information

Article History

Received: 30 May 2022

Accepted: 17 October 2022

First Online: 28 October 2022

Declarations

:

: All animal experiments were approved by the Ethics Committee of Wuhan Institute of Virology (Approval number: WIVA04202102).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below